Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Regeneron Pharmaceuticals Inc : Regeneron Pharmaceuticals Assigned Patent

12/31/2013 | 03:06am US/Eastern
Recommend:
0

By Targeted News Service

ALEXANDRIA, Va., Dec. 31 -- Regeneron Pharmaceuticals, Tarrytown, N.Y., has been assigned a patent (8,613,927) developed by five co-inventors for a "high affinity human antibodies to human nerve growth factor." The co-inventors are Lynn MacDonald, White Plains, N.Y., Richard Torres, New York, Marc R. Morra, Beacon Falls, Conn., Joel H. Martin, Putnam Valley, N.Y., and Joel C. Reinhardt, Mount Kisco, N.Y.

The patent application was filed on Feb. 28, 2012 (13/406,734). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=3&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=141&f=G&l=50&co1=AND&d=PTXT&s1=20131224.PD.&s2=%28NY.ASST.%29&OS=ISD/12/24/2013+AND+AS/NY&RS=ISD/12/24/2013+AND+AS/NY

Written by Sudarshan Harpal; edited by Jaya Anand.

SH1231JA1231-963857

© Targeted News Service, Acquiremedia 2014
Recommend :
0
React to this article
Latest news on REGENERON PHARMACEUTICALS
5d ago REGENERON PHARMACEUTICALS : Two-Year Results From Phase 3 VIVID-DME Trial of EYL..
5d ago REGENERON PHARMACEUTICALS : Schedules Release of Q2 2014 Financial Results
07/18 REGENERON PHARMACEUTICALS : and Sanofi Report Dupilumab Study Results
07/18 REGENERON PHARMACEUTICALS : to Report Second Quarter 2014 Financial and Operatin..
07/18 REGENERON PHARMACEUTICALS : Two-Year Results From Phase 3 VIVID-DME Trial of EYL..
07/16 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Results from Phase 2b S..
07/14 REGENERON PHARMACEUTICALS : Assigned Patent
07/14 REGENERON PHARMACEUTICALS : and Sanofi Report Dupilumab Study Results
07/11 SANOFI : Drug affords significant eczema relief: Companies
07/09 REGENERON PHARMACEUTICALS : Researchers Submit Patent Application, "Compositions..
Advertisement
Chart
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
Regeneron Pharmaceuticals  : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF